Teachers Retirement System of The State of Kentucky Acquires New Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Teachers Retirement System of The State of Kentucky acquired a new stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Get Rating) in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 29,767 shares of the company’s stock, valued at approximately $9,698,000.

A number of other large investors also recently bought and sold shares of the business. BlackRock Inc. boosted its holdings in IDEXX Laboratories by 4.2% during the 3rd quarter. BlackRock Inc. now owns 8,792,300 shares of the company’s stock valued at $2,864,533,000 after acquiring an additional 358,427 shares during the period. State Street Corp raised its position in IDEXX Laboratories by 3.6% during the 3rd quarter. State Street Corp now owns 3,784,353 shares of the company’s stock valued at $1,232,942,000 after purchasing an additional 132,091 shares in the last quarter. Alliancebernstein L.P. raised its position in IDEXX Laboratories by 4.6% during the 3rd quarter. Alliancebernstein L.P. now owns 2,906,690 shares of the company’s stock valued at $947,000,000 after purchasing an additional 128,011 shares in the last quarter. FMR LLC raised its position in IDEXX Laboratories by 82.5% during the 2nd quarter. FMR LLC now owns 2,067,814 shares of the company’s stock valued at $725,243,000 after purchasing an additional 934,829 shares in the last quarter. Finally, Brown Advisory Inc. raised its position in IDEXX Laboratories by 16.4% during the 3rd quarter. Brown Advisory Inc. now owns 1,212,028 shares of the company’s stock valued at $394,880,000 after purchasing an additional 170,834 shares in the last quarter. Hedge funds and other institutional investors own 87.90% of the company’s stock.

IDEXX Laboratories Stock Up 2.0 %

Shares of IDXX stock opened at $474.11 on Friday. IDEXX Laboratories, Inc. has a 1-year low of $317.06 and a 1-year high of $560.92. The stock’s fifty day moving average price is $481.01 and its 200 day moving average price is $413.89. The company has a debt-to-equity ratio of 1.14, a current ratio of 0.89 and a quick ratio of 0.59. The company has a market cap of $39.30 billion, a price-to-earnings ratio of 59.04, a price-to-earnings-growth ratio of 2.67 and a beta of 1.18.

IDEXX Laboratories (NASDAQ:IDXX – Get Rating) last announced its earnings results on Monday, February 6th. The company reported $2.05 earnings per share for the quarter, topping the consensus estimate of $1.92 by $0.13. IDEXX Laboratories had a return on equity of 124.51% and a net margin of 20.17%. The firm had revenue of $828.60 million for the quarter, compared to the consensus estimate of $820.91 million. During the same period in the previous year, the business earned $1.89 EPS. The firm’s revenue for the quarter was up 3.4% on a year-over-year basis. On average, research analysts expect that IDEXX Laboratories, Inc. will post 9.58 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on IDXX shares. The Goldman Sachs Group lifted their target price on IDEXX Laboratories from $465.00 to $530.00 and gave the company a “buy” rating in a research report on Wednesday, January 25th. Atlantic Securities lifted their target price on IDEXX Laboratories from $470.00 to $600.00 and gave the company an “overweight” rating in a research report on Tuesday, February 7th. StockNews.com began coverage on IDEXX Laboratories in a research report on Thursday. They set a “buy” rating for the company. TheStreet raised IDEXX Laboratories from a “c+” rating to a “b-” rating in a research report on Friday, November 25th. Finally, JPMorgan Chase & Co. boosted their price target on IDEXX Laboratories from $525.00 to $550.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 7th. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $514.75.

Insider Buying and Selling

In related news, SVP Kathy V. Turner sold 2,000 shares of the business’s stock in a transaction on Tuesday, February 14th. The stock was sold at an average price of $504.59, for a total transaction of $1,009,180.00. Following the transaction, the senior vice president now directly owns 7,380 shares in the company, valued at approximately $3,723,874.20. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In other IDEXX Laboratories news, SVP Kathy V. Turner sold 2,000 shares of the business’s stock in a transaction dated Tuesday, February 14th. The stock was sold at an average price of $504.59, for a total transaction of $1,009,180.00. Following the sale, the senior vice president now owns 7,380 shares in the company, valued at approximately $3,723,874.20. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Kathy V. Turner sold 1,000 shares of the business’s stock in a transaction dated Thursday, February 9th. The shares were sold at an average price of $505.04, for a total value of $505,040.00. Following the sale, the senior vice president now owns 6,941 shares in the company, valued at approximately $3,505,482.64. The disclosure for this sale can be found here. 2.06% of the stock is owned by company insiders.

IDEXX Laboratories Profile

(Get Rating)

IDEXX Laboratories, Inc engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy, and water testing markets. It operates through the following segments: Companion Animal Group (CAG), Water Quality Products (Water), Livestock, Poultry, and Dairy (LPD), and Other.